Form 8-K - Current report:
SEC Accession No. 0001326732-25-000005
Filing Date
2025-02-13
Accepted
2025-02-13 08:00:20
Documents
15
Period of Report
2025-02-07
Items
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xncr-20250207.htm   iXBRL 8-K 40091
2 EX-7.1 xencor8-krsmresponse_fin.htm EX-7.1 1041
6 xencor8-krsmresponse_fin001.jpg GRAPHIC 64286
  Complete submission text file 0001326732-25-000005.txt   257551

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xncr-20250207.xsd EX-101.SCH 1779
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xncr-20250207_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xncr-20250207_pre.xml EX-101.PRE 12506
17 EXTRACTED XBRL INSTANCE DOCUMENT xncr-20250207_htm.xml XML 2728
Mailing Address 465 N. HALSTEAD ST. SUITE 200 PASADENA CA 91107
Business Address 465 N. HALSTEAD ST. SUITE 200 PASADENA CA 91107 626-305-5900
Xencor Inc (Filer) CIK: 0001326732 (see all company filings)

EIN.: 201622502 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36182 | Film No.: 25617254
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)